Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM78NWP)

• Drug Name: Dostarlimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Approved	[1]
Neoplasm	2A00-2F9Z	Phase 3	[2]
Breast cancer	2C60-2C65	Phase 2	[3]
Multiple myeloma	2A83	Phase 2	[4]

• Cross-matching ID: TTD Drug ID: DM78NWP

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	5.635	4.661	4.706	5.15

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Endometrial cancer
• ICD Disease Classification: 2C76

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	7.26E-01	-0.01	-0.03

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [2] ClinicalTrials.gov (NCT03981796) A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
• [5] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.